Lylia Sivcheva

690 total citations
7 papers, 41 citations indexed

About

Lylia Sivcheva is a scholar working on Genetics, Rheumatology and Oncology. According to data from OpenAlex, Lylia Sivcheva has authored 7 papers receiving a total of 41 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Genetics, 7 papers in Rheumatology and 4 papers in Oncology. Recurrent topics in Lylia Sivcheva's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers), Eosinophilic Disorders and Syndromes (6 papers) and Cytokine Signaling Pathways and Interactions (4 papers). Lylia Sivcheva is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers), Eosinophilic Disorders and Syndromes (6 papers) and Cytokine Signaling Pathways and Interactions (4 papers). Lylia Sivcheva collaborates with scholars based in France, Austria and Hungary. Lylia Sivcheva's co-authors include Halyna Pylypenko, Jean‐Jacques Kiladjian, Vera Yablokova, Miklós Egyed, Christoph Klade, Pencho Georgiev, Liana Gercheva, Jiřı́ Mayer, Dorota Krochmalczyk and Hans Carl Hasselbalch and has published in prestigious journals such as Blood, HemaSphere and SSRN Electronic Journal.

In The Last Decade

Lylia Sivcheva

7 papers receiving 41 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lylia Sivcheva France	5	35	26	24	17	3	7	41
Vera Yablokova France	5	36 1.0×	27 1.0×	24 1.0×	17 1.0×	4 1.3×	8	43
Kim‐Hien T. Dao United States	2	47 1.3×	13 0.5×	49 2.0×	17 1.0×	2 0.7×	4	63
Pascale Cony Makhoul France	4	26 0.7×	15 0.6×	26 1.1×	11 0.6×	8 2.7×	11	39
Federico Sackmann Argentina	4	31 0.9×	20 0.8×	22 0.9×	29 1.7×	13 4.3×	8	51
Francesca Nice United Kingdom	3	37 1.1×	8 0.3×	34 1.4×	26 1.5×	2 0.7×	3	50
Xénia Cabagnols France	3	36 1.0×	9 0.3×	30 1.3×	60 3.5×	3 1.0×	3	74
Mihaela Lazaroiu Singapore	5	51 1.5×	13 0.5×	46 1.9×	31 1.8×		9	59
Fausto Palmieri Italy	2	57 1.6×	20 0.8×	41 1.7×	42 2.5×	9 3.0×	5	75
Pietro Perini Italy	4	26 0.7×	6 0.2×	24 1.0×	15 0.9×	9 3.0×	5	42
Yervand Hakobyan Armenia	4	32 0.9×	47 1.8×	16 0.7×	10 0.6×	12 4.0×	13	66

Countries citing papers authored by Lylia Sivcheva

Since Specialization

Citations

This map shows the geographic impact of Lylia Sivcheva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lylia Sivcheva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lylia Sivcheva more than expected).

Fields of papers citing papers by Lylia Sivcheva

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lylia Sivcheva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lylia Sivcheva. The network helps show where Lylia Sivcheva may publish in the future.

Co-authorship network of co-authors of Lylia Sivcheva

This figure shows the co-authorship network connecting the top 25 collaborators of Lylia Sivcheva. A scholar is included among the top collaborators of Lylia Sivcheva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lylia Sivcheva. Lylia Sivcheva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

Kiladjian, Jean‐Jacques, Christoph Klade, Pencho Georgiev, et al.. (2022). Efficacy and Safety of Long-Term Ropeginterferon Alfa-2b Treatment in Patients with Low-Risk and High-Risk Polycythemia Vera (PV). Blood. 140(Supplement 1). 9663–9664. 3 indexed citations

Gisslinger, Heinz, Christoph Klade, Pencho Georgiev, et al.. (2021). Polycythemia Vera Patients Respond Better to Ropeginterferon Alfa-2b Than HU/BAT Irrespective of Pretreatment or Mutational Status; Results from 5 Years' Treatment in a Randomized, Controlled Setting in the PROUD-PV/Continuation-PV Trials. Blood. 138(Supplement 1). 3660–3660. 1 indexed citations

Gisslinger, Heinz, Christoph Klade, Pencho Georgiev, et al.. (2020). Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: 5-Year Results from a Randomized Controlled Study and Its Extension. Blood. 136(Supplement 1). 33–33. 10 indexed citations

Gisslinger, Heinz, Christoph Klade, Pencho Georgiev, et al.. (2020). Ropeginterferon Alfa‐2b: Efficacy and Safety in Different Age Groups. HemaSphere. 4(6). e485–e485. 4 indexed citations

Gisslinger, Heinz, Christoph Klade, Pencho Georgiev, et al.. (2019). Ropeginterferon Alfa-2b versus Standard Therapy for Polycythaemia Vera; a Randomised, Controlled, Phase III Trial. SSRN Electronic Journal. 5 indexed citations

Kiladjian, Jean‐Jacques, Christoph Klade, Pencho Georgiev, et al.. (2019). Thromboembolic Risk Reduction and High Rate of Complete Molecular Response with Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: Results from a Randomized Controlled Study. Blood. 134(Supplement_1). 553–553. 4 indexed citations

Gisslinger, Heinz, Christoph Klade, Pencho Georgiev, et al.. (2018). Evidence for Superior Efficacy and Disease Modification after Three Years of Prospective Randomized Controlled Treatment of Polycythemia Vera Patients with Ropeginterferon Alfa-2b Vs. HU/BAT. Blood. 132(Supplement 1). 579–579. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact